162 related articles for article (PubMed ID: 23937224)
1. Metformin in lung cancer: rationale for a combination therapy.
Morgillo F; Sasso FC; Della Corte CM; Festino L; Manzo A; Martinelli E; Troiani T; Capuano A; Ciardiello F
Expert Opin Investig Drugs; 2013 Nov; 22(11):1401-9. PubMed ID: 23937224
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
Morgillo F; Sasso FC; Della Corte CM; Vitagliano D; D'Aiuto E; Troiani T; Martinelli E; De Vita F; Orditura M; De Palma R; Ciardiello F
Clin Cancer Res; 2013 Jul; 19(13):3508-19. PubMed ID: 23695170
[TBL] [Abstract][Full Text] [Related]
3. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes.
Tan BX; Yao WX; Ge J; Peng XC; Du XB; Zhang R; Yao B; Xie K; Li LH; Dong H; Gao F; Zhao F; Hou JM; Su JM; Liu JY
Cancer; 2011 Nov; 117(22):5103-11. PubMed ID: 21523768
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
Chen H; Yao W; Chu Q; Han R; Wang Y; Sun J; Wang D; Wang Y; Cao M; He Y
Cancer Lett; 2015 Dec; 369(1):97-102. PubMed ID: 26341687
[TBL] [Abstract][Full Text] [Related]
5. Metformin use and survival from lung cancer: A population-based cohort study.
Menamin ÚC; Cardwell CR; Hughes CM; Murray LM
Lung Cancer; 2016 Apr; 94():35-9. PubMed ID: 26973204
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial.
Fasano M; Della Corte CM; Capuano A; Sasso FC; Papaccio F; Berrino L; Ciardiello F; Morgillo F
Clin Lung Cancer; 2015 Jan; 16(1):57-9. PubMed ID: 25242667
[TBL] [Abstract][Full Text] [Related]
7. Fixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention.
Seabloom DE; Galbraith AR; Haynes AM; Antonides JD; Wuertz BR; Miller WA; Miller KA; Steele VE; Miller MS; Clapper ML; O'Sullivan MG; Ondrey FG
Cancer Prev Res (Phila); 2017 Feb; 10(2):116-123. PubMed ID: 28052934
[TBL] [Abstract][Full Text] [Related]
8. Metformin in breast cancer: time for action.
Goodwin PJ; Ligibel JA; Stambolic V
J Clin Oncol; 2009 Jul; 27(20):3271-3. PubMed ID: 19487373
[No Abstract] [Full Text] [Related]
9. Metformin for non-small cell lung cancer patients: Opportunities and pitfalls.
Levy A; Doyen J
Crit Rev Oncol Hematol; 2018 May; 125():41-47. PubMed ID: 29650275
[TBL] [Abstract][Full Text] [Related]
10. Is there still a role for mitomycin-based combination chemotherapy in treating patients with nonsmall cell lung cancer? A single institution experience.
Vitale FV; Malaponte E; Calì S; Antonelli G; Panebianco V; Blandino R; Ferraù F
J Oncol Pharm Pract; 2013 Sep; 19(3):202-7. PubMed ID: 23034407
[TBL] [Abstract][Full Text] [Related]
11. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
12. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
[TBL] [Abstract][Full Text] [Related]
13. Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy.
Barner JC
Clin Ther; 2011 Sep; 33(9):1281-8. PubMed ID: 21840054
[TBL] [Abstract][Full Text] [Related]
14. The role of targeted agents in adjuvant therapy for non-small cell lung cancer.
Kelly K
Clin Cancer Res; 2005 Jul; 11(13 Pt 2):5027s-5029s. PubMed ID: 16000608
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
Carter CA; Chen C; Brink C; Vincent P; Maxuitenko YY; Gilbert KS; Waud WR; Zhang X
Cancer Chemother Pharmacol; 2007 Feb; 59(2):183-95. PubMed ID: 16724239
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy in the treatment of non-small cell lung cancer.
Hainsworth JD
Am Fam Physician; 1997 May; 55(6):2265-72. PubMed ID: 9149654
[TBL] [Abstract][Full Text] [Related]
17. Molecularly targeted therapies in locally advanced non-small-cell lung cancer.
Devarakonda S; Morgensztern D; Govindan R
Clin Lung Cancer; 2013 Sep; 14(5):467-72. PubMed ID: 23684057
[TBL] [Abstract][Full Text] [Related]
18. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
Maione P; Gridelli C; Troiani T; Ciardiello F
Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
[TBL] [Abstract][Full Text] [Related]
19. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in chemotherapy for lung cancer.
Lilenbaum RC
Curr Opin Pulm Med; 1996 Jul; 2(4):285-9. PubMed ID: 9363153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
